Tsunekazu Hishima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tsunekazu Hishima has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Yusuke Okuma
Department of Thoracic Oncology, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
8 shared publications - Yukio Hosomi
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
7 shared publications Koichi Koizumi
Department of Gastroenterology, Tokyo Metropolitan Komagome Hospital
4 shared publicationsShingo Miyamoto
4 shared publicationsTaku Tabata
Department of Hematology, Tokyo Metropolitan Komagome Hospital
4 shared publicationsYoshiharu Maeda
Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious diseases Center, Bunkyo, Tokyo, Japan
4 shared publications
Latest Publications
- Open Access
- 25 January 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 808396
CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets
CD70 – a ligand protein of CD27 on lymphocytes – is expressed in a large spectrum of malignancies. It is an attractive target for antibody-based therapy and several clinical trials are currently being conducted. However, there is no evidence regarding the expression of CD70 and its relationship with expression of programmed death ligand-1 (PD-L1) and CD27+ tumor-infiltrating lymphocytes (TIL) in formalin-fixed paraffin-embedded (FFPE) tissues of thymic tumors. FFPE tissues of thymic squamous cell carcinoma (TSCC) (operative specimens, n = 31; biopsy specimens, n = 11), thymoma (n = 60), thymic carcinoid (n = 3), and lung squamous cell carcinoma (LSCC) (n = 30) were analyzed immunohistochemically. Immunoreactivity for CD70 was semi-quantitatively scored according to the proportion of positive tumor cells. Moreover, the densities of CD27-positive intratumoral TIL (iTIL) and stromal TIL of TSCC were assessed and survival was compared. Most TSCC cases (87%; 27/31) were CD70-positive. In contrast, all thymoma and thymic carcinoid cases were CD70-negative. In LSCC cases, CD70-positivity was significantly lower than TSCC cases (20%; 6/30). Biopsy and resected specimens obtained from the same patients demonstrated a consistent staining pattern (6/6 patients). The proportion of CD70-positive TSCC was comparable with those of CD5 (87%) and CD117 (90%). Correlation between CD70 and PD-L1 expression score was observed. There was no significant difference in survival between the CD70-high and CD70-low expression groups. Meanwhile, patients with CD27-positive iTIL-high tumors exhibited better survival than those with iTIL-low tumors. This tendency was weaker in the CD70-high subset. CD70 immunohistochemistry is useful in diagnosing TSCC. CD70 may prevent anti-tumor immunity via CD27. Immunotherapy targeting the CD70–CD27 axis may be a promising option for the treatment of TSCC.
- 25 January 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 808396
Open AccessCD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic Targets
CD70 – a ligand protein of CD27 on lymphocytes – is expressed in a large spectrum of malignancies. It is an attractive target for antibody-based therapy and several clinical trials are currently being conducted. However, there is no evidence regarding the expression of CD70 and its relationship with expression of programmed death ligand-1 (PD-L1) and CD27+ tumor-infiltrating lymphocytes (TIL) in formalin-fixed paraffin-embedded (FFPE) tissues of thymic tumors. FFPE tissues of thymic squamous cell carcinoma (TSCC) (operative specimens, n = 31; biopsy specimens, n = 11), thymoma (n = 60), thymic carcinoid (n = 3), and lung squamous cell carcinoma (LSCC) (n = 30) were analyzed immunohistochemically. Immunoreactivity for CD70 was semi-quantitatively scored according to the proportion of positive tumor cells. Moreover, the densities of CD27-positive intratumoral TIL (iTIL) and stromal TIL of TSCC were assessed and survival was compared. Most TSCC cases (87%; 27/31) were CD70-positive. In contrast, all thymoma and thymic carcinoid cases were CD70-negative. In LSCC cases, CD70-positivity was significantly lower than TSCC cases (20%; 6/30). Biopsy and resected specimens obtained from the same patients demonstrated a consistent staining pattern (6/6 patients). The proportion of CD70-positive TSCC was comparable with those of CD5 (87%) and CD117 (90%). Correlation between CD70 and PD-L1 expression score was observed. There was no significant difference in survival between the CD70-high and CD70-low expression groups. Meanwhile, patients with CD27-positive iTIL-high tumors exhibited better survival than those with iTIL-low tumors. This tendency was weaker in the CD70-high subset. CD70 immunohistochemistry is useful in diagnosing TSCC. CD70 may prevent anti-tumor immunity via CD27. Immunotherapy targeting the CD70–CD27 axis may be a promising option for the treatment of TSCC.
- 1 January 2022
- Published by Elsevier in Laboratory Investigation
- Vol. 35 (1) , 33-43
Sweat-gland carcinoma with neuroendocrine differentiation (SCAND): a clinicopathologic study of 13 cases with genetic analysis
- 1 January 2022
- Published by Elsevier in Laboratory Investigation
- Vol. 35 (1) , 33-43
Sweat-gland carcinoma with neuroendocrine differentiation (SCAND): a clinicopathologic study of 13 cases with genetic analysis
- Open Access
- 25 January 2021
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 11 (1) , 1-9
Primary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
Extramedullary hematopoiesis is widely known to occur in patients with primary myelofibrosis (PMF). Autopsy studies on individuals with PMF revealed that extramedullary hematopoiesis occurred in the kidneys in 35% of the cases, but there is little awareness regarding such lesions. A 63-year-old man was diagnosed with PMF based on a detailed examination of persistent high white blood cells. An examination of the patient’s medical records revealed an increased white blood cell count, deterioration of kidney function, and urinary protein excretion developed simultaneously. Thus, a kidney biopsy was performed. Advanced lymphocyte invasion was recognized in the interstitial tissue, and the tubular structure was highly disrupted. Based on these findings, he was diagnosed with interstitial nephritis. However, because of the large number of cells with nuclear atypia in the stroma, additional immunohistochemical staining was also performed, such as glycophorin A, naphthol AS-D, myeloperoxidase, and CD42b. As a result, invasion of three lineages of immature cells, erythroblasts, megakaryocytes, and granulocytes, was identified. Renal dysfunction resulting from interstitial cellular infiltration due to extramedullary hematopoiesis was therefore diagnosed. Treatment with ruxolitinib was initiated after a renal biopsy and the rate of decline in renal function was slightly reduced. Although, in myeloproliferative disorders, proliferative glomerular lesions are widely considered to be renal disorders, there is little awareness regarding interstitial lesions. Extramedullary hematopoiesis of the kidney in PMF is not uncommon, but 40% of cases are reportedly misdiagnosed as interstitial nephritis. Because extramedullary hematopoiesis can be controlled by ruxolitinib, early detection is important.
- 25 January 2021
- Published by S. Karger AG in Case Reports in Nephrology and Dialysis
- Vol. 11 (1) , 1-9
Open AccessPrimary Myelofibrosis-Related Renal Disorders Treated with a Janus Kinase Inhibitor
Extramedullary hematopoiesis is widely known to occur in patients with primary myelofibrosis (PMF). Autopsy studies on individuals with PMF revealed that extramedullary hematopoiesis occurred in the kidneys in 35% of the cases, but there is little awareness regarding such lesions. A 63-year-old man was diagnosed with PMF based on a detailed examination of persistent high white blood cells. An examination of the patient’s medical records revealed an increased white blood cell count, deterioration of kidney function, and urinary protein excretion developed simultaneously. Thus, a kidney biopsy was performed. Advanced lymphocyte invasion was recognized in the interstitial tissue, and the tubular structure was highly disrupted. Based on these findings, he was diagnosed with interstitial nephritis. However, because of the large number of cells with nuclear atypia in the stroma, additional immunohistochemical staining was also performed, such as glycophorin A, naphthol AS-D, myeloperoxidase, and CD42b. As a result, invasion of three lineages of immature cells, erythroblasts, megakaryocytes, and granulocytes, was identified. Renal dysfunction resulting from interstitial cellular infiltration due to extramedullary hematopoiesis was therefore diagnosed. Treatment with ruxolitinib was initiated after a renal biopsy and the rate of decline in renal function was slightly reduced. Although, in myeloproliferative disorders, proliferative glomerular lesions are widely considered to be renal disorders, there is little awareness regarding interstitial lesions. Extramedullary hematopoiesis of the kidney in PMF is not uncommon, but 40% of cases are reportedly misdiagnosed as interstitial nephritis. Because extramedullary hematopoiesis can be controlled by ruxolitinib, early detection is important.
- Open Access
- 1 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2473
Clinicopathological Factors Related to Recurrence Patterns of Resected Non-Small Cell Lung Cancer
Even after complete resection, non-small cell lung cancer (NSCLC) shows preferential recurrence in the mediastinal lymph nodes, lungs, brain, bone, liver, and adrenal gland. However, the relationship between clinicopathological factors and recurrence patterns after resection has not been well-evaluated. Among 688 NSCLC cases with complete resection between 2004 and 2016, 233 cases recurred at our institute. On multivariate analyses, NSCLCs with lymph node metastasis and pulmonary metastasis at surgery commonly recurred in the mediastinal lymph nodes and lungs, respectively. Young age, adenocarcinoma, and vascular invasion were correlated with brain metastasis. Although no variable was associated with bone metastasis, vascular invasion was correlated with postoperative liver and adrenal gland metastasis. Pathologically proven stage II or III NSCLC, adenocarcinoma, and the presence of lymphatic permeation would result in multiple metastases. Vascular invasion, larger invasive size, and advanced stage were independent risk factors of early recurrence. Considering survival, vascular invasion, elderly age, and non-adenocarcinoma were unfavorable prognostic factors after recurrence. Some clinicopathological variables were correlated with organ-specific metastasis and post-recurrence survival. Particularly, vascular invasion was a biomarker of brain, liver, and adrenal gland metastases and a prognostic marker after recurrence among completely resected NSCLC. This information is useful for more frequent patient follow-up and identifying organ-specific distant metastasis.
- 1 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2473
Open AccessClinicopathological Factors Related to Recurrence Patterns of Resected Non-Small Cell Lung Cancer
Even after complete resection, non-small cell lung cancer (NSCLC) shows preferential recurrence in the mediastinal lymph nodes, lungs, brain, bone, liver, and adrenal gland. However, the relationship between clinicopathological factors and recurrence patterns after resection has not been well-evaluated. Among 688 NSCLC cases with complete resection between 2004 and 2016, 233 cases recurred at our institute. On multivariate analyses, NSCLCs with lymph node metastasis and pulmonary metastasis at surgery commonly recurred in the mediastinal lymph nodes and lungs, respectively. Young age, adenocarcinoma, and vascular invasion were correlated with brain metastasis. Although no variable was associated with bone metastasis, vascular invasion was correlated with postoperative liver and adrenal gland metastasis. Pathologically proven stage II or III NSCLC, adenocarcinoma, and the presence of lymphatic permeation would result in multiple metastases. Vascular invasion, larger invasive size, and advanced stage were independent risk factors of early recurrence. Considering survival, vascular invasion, elderly age, and non-adenocarcinoma were unfavorable prognostic factors after recurrence. Some clinicopathological variables were correlated with organ-specific metastasis and post-recurrence survival. Particularly, vascular invasion was a biomarker of brain, liver, and adrenal gland metastases and a prognostic marker after recurrence among completely resected NSCLC. This information is useful for more frequent patient follow-up and identifying organ-specific distant metastasis.
- Open Access
- 1 January 2020
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 26 (1) , 178-188
Distribution of Transplantation-Associated Thrombotic Microangiopathy (TA-TMA) and Comparison between Renal TA-TMA and Intestinal TA-TMA: Autopsy Study
- 1 January 2020
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 26 (1) , 178-188
Open AccessDistribution of Transplantation-Associated Thrombotic Microangiopathy (TA-TMA) and Comparison between Renal TA-TMA and Intestinal TA-TMA: Autopsy Study
- 13 February 2019
- Published by Springer Nature in Virchows Archiv
- Vol. 475 (1) , 115-119
A first case of primary gastric verrucous carcinoma with isolated squamous epithelium in the stomach
Primary gastric squamous cell carcinoma (SCC) is a rare histological subtype of gastric cancer. Here, we report the first case of primary gastric verrucous carcinoma (VC), a well-differentiated variant of SCC. Gastroscopy revealed a papillary polypoid lesion at the posterior wall of the upper gastric body and isolated squamous epithelium at the greater curvature of the fornix in a 78-year-old woman. Endoscopic submucosal dissection was performed. Microscopically, the lesion comprised very well-differentiated squamous epithelium with minimal atypia and exhibited coarse papillary structure and bulbous epithelial downgrowth with submucosal invasion. Conventional SCC or adenocarcinoma components were not included, and the lesion was surrounded by the metaplastic intestinal mucosa. Human papillomavirus infection was not detected. Although the pathogenesis of primary gastric SCC remains controversial, here, the disease is suggested as having originated from squamous epithelium. Knowledge of primary gastric VC and difficulty in diagnosing it using surface biopsy is necessary.
- 13 February 2019
- Published by Springer Nature in Virchows Archiv
- Vol. 475 (1) , 115-119
A first case of primary gastric verrucous carcinoma with isolated squamous epithelium in the stomach
Primary gastric squamous cell carcinoma (SCC) is a rare histological subtype of gastric cancer. Here, we report the first case of primary gastric verrucous carcinoma (VC), a well-differentiated variant of SCC. Gastroscopy revealed a papillary polypoid lesion at the posterior wall of the upper gastric body and isolated squamous epithelium at the greater curvature of the fornix in a 78-year-old woman. Endoscopic submucosal dissection was performed. Microscopically, the lesion comprised very well-differentiated squamous epithelium with minimal atypia and exhibited coarse papillary structure and bulbous epithelial downgrowth with submucosal invasion. Conventional SCC or adenocarcinoma components were not included, and the lesion was surrounded by the metaplastic intestinal mucosa. Human papillomavirus infection was not detected. Although the pathogenesis of primary gastric SCC remains controversial, here, the disease is suggested as having originated from squamous epithelium. Knowledge of primary gastric VC and difficulty in diagnosing it using surface biopsy is necessary.
- Open Access
- 4 February 2019
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 36 (2) , 130-133
Progressive hepatic cirrhosis early after allogeneic hematopoietic stem cell transplantation in a 5 patient with chronic hepatitis C infection
- 4 February 2019
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 36 (2) , 130-133
Open AccessProgressive hepatic cirrhosis early after allogeneic hematopoietic stem cell transplantation in a 5 patient with chronic hepatitis C infection
- Open Access
- 17 January 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 65
Unusual manifestation of disseminated herpes simplex virus type 2 infection associated with pharyngotonsilitis, esophagitis, and hemophagocytic lymphohisitocytosis without genital involvement
Herpes simplex virus (HSV) has various presentations, depending on the patient’s immune status, age, and the route of transmission. In adults, HSV type 1 is found predominantly in the oral area, and HSV type 2 (HSV-2) is commonly found in the genital area. HSV-2 infection without genital lesions is uncommon. Herein we report a unique case of pharyngotonsillitis as an initial manifestation of disseminated HSV-2 infection without genital involvement. A 46-year-old male was admitted to our hospital with a 1-week history of fever and sore throat. His past medical history included hypereosinophilic syndrome diagnosed at age 45 years. Physical examination revealed throat congestion, bilaterally enlarged tonsils with exudates, tender cervical lymphadenopathy in the left posterior triangle, and mild epigastric tenderness. The laboratory data demonstrated bicytopenia, elevated liver enzyme levels, and hyperferritinemia. A bone marrow smear showed hypocellular marrow with histiocytes and hemophagocytosis. The diagnosis of HLH was confirmed, and the patient was treated with methylprednisolone pulse therapy on days 1–3. On day 5, despite initial improvement of the fever and sore throat, multiple, new, small bullae developed on the patient’s face, trunk, and extremities. Additional testing showed that he was positive for HSV-specific immunoglobulin M and immunoglobulin G. Disseminated HSV infection was suspected, and intravenous acyclovir (10 mg/kg every 8 h) was begun. A subsequent direct antigen test of a bulla sample was positive for HSV-2. Moreover, tonsillar and esophageal biopsies revealed viral inclusion bodies. Immunohistochemical staining and a quantitative real-time polymerase chain reaction (PCR) assay confirmed the presence of HSV-2. Disseminated HSV-2 infection with multiple bullae, tonsillitis, esophagitis, and suspected hepatic involvement was diagnosed. After a 2-week course of intravenous acyclovir, his hematological status and liver function normalized, and his cutaneous skin lesions resolved. He was discharged on day 22 in good general health and continued taking oral valacyclovir for viral suppression due to his immunosuppressed status. Disseminated HSV-2 infection should be considered as one of the differential diagnoses in patients with pharyngotonsillitis and impaired liver function of unknown etiology even if there are no genital lesions.
- 17 January 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 65
Open AccessUnusual manifestation of disseminated herpes simplex virus type 2 infection associated with pharyngotonsilitis, esophagitis, and hemophagocytic lymphohisitocytosis without genital involvement
Herpes simplex virus (HSV) has various presentations, depending on the patient’s immune status, age, and the route of transmission. In adults, HSV type 1 is found predominantly in the oral area, and HSV type 2 (HSV-2) is commonly found in the genital area. HSV-2 infection without genital lesions is uncommon. Herein we report a unique case of pharyngotonsillitis as an initial manifestation of disseminated HSV-2 infection without genital involvement. A 46-year-old male was admitted to our hospital with a 1-week history of fever and sore throat. His past medical history included hypereosinophilic syndrome diagnosed at age 45 years. Physical examination revealed throat congestion, bilaterally enlarged tonsils with exudates, tender cervical lymphadenopathy in the left posterior triangle, and mild epigastric tenderness. The laboratory data demonstrated bicytopenia, elevated liver enzyme levels, and hyperferritinemia. A bone marrow smear showed hypocellular marrow with histiocytes and hemophagocytosis. The diagnosis of HLH was confirmed, and the patient was treated with methylprednisolone pulse therapy on days 1–3. On day 5, despite initial improvement of the fever and sore throat, multiple, new, small bullae developed on the patient’s face, trunk, and extremities. Additional testing showed that he was positive for HSV-specific immunoglobulin M and immunoglobulin G. Disseminated HSV infection was suspected, and intravenous acyclovir (10 mg/kg every 8 h) was begun. A subsequent direct antigen test of a bulla sample was positive for HSV-2. Moreover, tonsillar and esophageal biopsies revealed viral inclusion bodies. Immunohistochemical staining and a quantitative real-time polymerase chain reaction (PCR) assay confirmed the presence of HSV-2. Disseminated HSV-2 infection with multiple bullae, tonsillitis, esophagitis, and suspected hepatic involvement was diagnosed. After a 2-week course of intravenous acyclovir, his hematological status and liver function normalized, and his cutaneous skin lesions resolved. He was discharged on day 22 in good general health and continued taking oral valacyclovir for viral suppression due to his immunosuppressed status. Disseminated HSV-2 infection should be considered as one of the differential diagnoses in patients with pharyngotonsillitis and impaired liver function of unknown etiology even if there are no genital lesions.
- 1 October 2018
- Published by AME Publishing Company in Mediastinum
- Vol. 2, AB007
AB007. OA01.07: CD70 in thymic carcinoma: a promising diagnostic marker
Background: CD70, one of tumor necrosis factor family protein, is reported to be expressed in a large spectrum of solid tumors and hematological malignancies. CD70 is an attractive target for antibody-based therapy and several clinical trials targeting CD70 are being conducted. We previously demonstrated CD70 expression was frequently observed on neoplastic epithelial cells of thymic squamous cell carcinoma (TSCC) via immunohistochemistry (IHC) with antibody for frozen section in the limited number of samples. There have been no reports of CD70 expression focusing on formalin fixed paraffin embedded (FFPE) thymic tumors. In this study, we investigated the utility of a CD70 antibody applied on routine FFPE tissues by assessing a larger number of thymic epithelial tumors, thymic carcinoids and lung squamous cell carcinomas (LSCCs). Methods: FFPE tissues of TSCC (operative specimens: n=34, biopsy specimens: n=11), thymoma (n=59), thymic carcinoid (n=3), and LSCC (n=30) obtained in a single institution were immunohistochemically analyzed with anti-CD70 antibody (TNFSF7, clone 301731, R&B systems) Immunoreactivity for CD70 were semi-quantitatively scored according to the proportion of positive cells. IHC of CD5 and CD117 was also performed. We compared mRNA level of CD70 from frozen tissues of TSCC (n=12) and certain subtypes of thymoma with little lymphocyte infiltration (type A: n=4, type B3: n=6) by quantitative real-time polymerase chain reaction (RT-PCR). Results: Seventy-nine percent (27/34) of TSCC cases were positive for CD70, meanwhile all thymoma including type B3 and thymic carcinoid cases were negative. Twenty percent (6/30) of LSCC cases were positive for CD70, but it was significantly lower than TSCC cases (PConclusions: CD70 immunohistochemistry with a paraffin section-reactive antibody is useful in distinguishing TSCC from histological mimickers such as type B3 thymoma and LSCC. TSCC may also be a promising candidate for immunotherapy targeting CD70.
- 1 October 2018
- Published by AME Publishing Company in Mediastinum
- Vol. 2, AB007
AB007. OA01.07: CD70 in thymic carcinoma: a promising diagnostic marker
Background: CD70, one of tumor necrosis factor family protein, is reported to be expressed in a large spectrum of solid tumors and hematological malignancies. CD70 is an attractive target for antibody-based therapy and several clinical trials targeting CD70 are being conducted. We previously demonstrated CD70 expression was frequently observed on neoplastic epithelial cells of thymic squamous cell carcinoma (TSCC) via immunohistochemistry (IHC) with antibody for frozen section in the limited number of samples. There have been no reports of CD70 expression focusing on formalin fixed paraffin embedded (FFPE) thymic tumors. In this study, we investigated the utility of a CD70 antibody applied on routine FFPE tissues by assessing a larger number of thymic epithelial tumors, thymic carcinoids and lung squamous cell carcinomas (LSCCs). Methods: FFPE tissues of TSCC (operative specimens: n=34, biopsy specimens: n=11), thymoma (n=59), thymic carcinoid (n=3), and LSCC (n=30) obtained in a single institution were immunohistochemically analyzed with anti-CD70 antibody (TNFSF7, clone 301731, R&B systems) Immunoreactivity for CD70 were semi-quantitatively scored according to the proportion of positive cells. IHC of CD5 and CD117 was also performed. We compared mRNA level of CD70 from frozen tissues of TSCC (n=12) and certain subtypes of thymoma with little lymphocyte infiltration (type A: n=4, type B3: n=6) by quantitative real-time polymerase chain reaction (RT-PCR). Results: Seventy-nine percent (27/34) of TSCC cases were positive for CD70, meanwhile all thymoma including type B3 and thymic carcinoid cases were negative. Twenty percent (6/30) of LSCC cases were positive for CD70, but it was significantly lower than TSCC cases (PConclusions: CD70 immunohistochemistry with a paraffin section-reactive antibody is useful in distinguishing TSCC from histological mimickers such as type B3 thymoma and LSCC. TSCC may also be a promising candidate for immunotherapy targeting CD70.
- Open Access
- 6 August 2018
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 67 (9) , 1477-1479
Correction to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer
The graphs are incorrectly identified in Fig. 3i, s and should be replaced with the following.
- 6 August 2018
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 67 (9) , 1477-1479
Open AccessCorrection to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer
The graphs are incorrectly identified in Fig. 3i, s and should be replaced with the following.